Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

63.24
0.0000
Volume:492.64K
Turnover:31.29M
Market Cap:7.49B
PE:24.70
High:64.00
Open:63.05
Low:62.68
Close:63.24
52wk High:82.22
52wk Low:47.50
Shares:118.47M
Float Shares:116.00M
Volume Ratio:0.28
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.56
EPS(LYR):2.56
ROE:153.59%
ROA:22.24%
PB:153.49
PE(LYR):24.70

Loading ...

Drug delivery firm Halozyme's Q3 adjusted EPS beats estimates

Reuters
·
Nov 04, 2025

Halozyme reports Q3 non-GAAP EPS $1.72, consensus $1.61

TIPRANKS
·
Nov 04, 2025

Halozyme Therapeutics Q3 Adj. EPS $1.72 Beats $1.63 Estimate, Sales $354.264M Beat $339.922M Estimate

Benzinga
·
Nov 04, 2025

Halozyme Therapeutics reports Q3 revenue of $354 million and net income of $175 million

Reuters
·
Nov 04, 2025

Halozyme Therapeutics Q3 EPS USD 1.43

THOMSON REUTERS
·
Nov 04, 2025

Halozyme Therapeutics Outlook FY Adjusted EPS USD 6.1-6.5

THOMSON REUTERS
·
Nov 04, 2025

Halozyme Therapeutics Outlook FY Revenue USD 1,300-1,375 Million

THOMSON REUTERS
·
Nov 04, 2025

Corrected-Halozyme Therapeutics Q3 Revenue USD 354.3 Million VS. Ibes Estimate USD 339.7 Million (Corrects Amount)

THOMSON REUTERS
·
Nov 04, 2025

Halozyme Raises 2025 Financial Guidance and Reports Strong Third Quarter 2025 Financial and Operating Results

THOMSON REUTERS
·
Nov 04, 2025

HALO Technologies Reports Strong Financial Growth and Strategic Expansion

TIPRANKS
·
Oct 31, 2025

Halozyme Therapeutics Is Maintained at Neutral by JP Morgan

Dow Jones
·
Oct 27, 2025

Halozyme Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Oct 20, 2025

Halozyme Therapeutics' Royalty Growth and Cost Control to Drive Q3 Earnings, Morgan Stanley Says

MT Newswires Live
·
Oct 20, 2025

Morgan Stanley Trims Price Target on Halozyme Therapeutics to $79 From $80, Keeps Overweight Rating

MT Newswires Live
·
Oct 20, 2025

Halozyme Therapeutics, Inc : Morgan Stanley Cuts Target Price to $79.00 From $80.00

THOMSON REUTERS
·
Oct 20, 2025

U.S. RESEARCH ROUNDUP- BlackRock, EQT, Ovintiv

Reuters
·
Oct 15, 2025

Halozyme Therapeutics Inc : Leerink Partners Raises to Market Perform From Underperform

THOMSON REUTERS
·
Oct 15, 2025

Halozyme Therapeutics Raised to Market Perform From Underperform by Leerink Partners

Dow Jones
·
Oct 15, 2025

Halozyme upgraded at Leerink on lower-than-feared Part B exposure

TIPRANKS
·
Oct 15, 2025

Halozyme upgraded to Market Perform from Underperform at Leerink

TIPRANKS
·
Oct 15, 2025